Cobitolimod

Drug Profile

Cobitolimod

Alternative Names: Antisense oligonucleotide NF-KB-p65; DIMS-0150; Kappaproct

Latest Information Update: 23 Jun 2017

Price : $50

At a glance

  • Originator InDex Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Genetic transcription modulators; NF-kappa B inhibitors; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ulcerative colitis
  • Phase I Brain oedema

Most Recent Events

  • 21 Jun 2017 Phase-II clinical trials in Ulcerative colitis in Ukraine, Spain, Serbia, Romania, Russia (Rectal) befor June 2017
  • 21 Jun 2017 InDex Pharmaceuticals initiates enrolment in the phase II CONDUCT trial for Ulcerative colitis in Czech Republic, France, Germany, Italy, Poland and Sweden (Rectal) before June 2017
  • 20 Apr 2017 InDex Pharmaceuticals initiates enrolment in the phase II CONDUCT trial for Ulcerative colitis in Hungary (EudraCT2016-004217-26)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top